Effect of rectal cancer treatment on tumor cells in blood

This trial is studying a blood test (CTC) for people with rectal cancer that hasn't spread to other parts of the body. It aims to see how the test relates to treatment outcomes after surgery.

This study looks at the long-term effects of rectal cancer treatment on gynecological and sexual health. It aims to understand how women recover after treatment, helping improve future care and support.

This study uses a special blood test to look for traces of tumor DNA (ctDNA) and compares it with information from your original tumor tissue or a new biopsy. It’s done in people with locally advanced rectal cancer who are going to receive standard chemotherapy and radiation, aiming to better track the cancer’s behavior.

This trial analyzes biological and clinical information from people who have had surgery for rectal cancer since 2019. It aims to better understand rectal tumors, which may help improve future treatments.

This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.

This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.